{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:14:30Z","timestamp":1792242870143,"version":"4.4.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"am","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Upadacitinib (UPA), an oral JAK1 inhibitor, has been associated with acne in up to 7% of patients with inflammatory bowel disease (IBD) in clinical trials. Emerging real-world evidence suggests the true prevalence may be higher, particularly among adolescents and young adults. This study evaluated the prevalence, age distribution, and impact of UPA-associated acne on treatment decisions in a real-world IBD cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional survey was conducted within a prospective IBD BioBank at a tertiary care center. All patients currently or previously treated with UPA (n\u2009=\u2009110) were invited to complete a 22-item electronic survey assessing acne history before and after UPA initiation, acne severity, treatments used, awareness of acne as a side effect, and influence on medication management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The survey was completed by 100 patients (91% response rate); 54% had Crohn\u2019s disease and 46% ulcerative colitis. The median age was 23\u2009years (IQR 18\u201335, range 7-66). Prior to UPA, 25% reported acne, predominantly mild. After starting UPA, 48% experienced new or worsening acne; 38% reported it as moderate, 29% as severe, and 46% sought dermatologic care. At time of survey (median 458\u2009days), 52% continued to have acne, well-controlled in only \u00bc with treatment; 5% had discontinued UPA due to acne. While 80% felt the benefits of UPA outweighed acne-related concerns, 7% disagreed\u2014despite most achieving clinical remission. Acne was significantly less prevalent at the extremes of age, &amp;lt;13 and &amp;gt;50 (P\u2009=\u20090.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Acne is a frequent and sometimes treatment-limiting side effect of UPA. Targeted counseling may support adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag036","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:47:42Z","timestamp":1776858462000},"source":"Crossref","is-referenced-by-count":1,"title":["Prevalence, Age-Distribution, and Impact on Management of Acne in Patients on Upadacitinib for Inflammatory Bowel Disease: Insights from a Single-Center Survey"],"prefix":"10.1093","author":[{"given":"Elizabeth A","family":"Spencer","sequence":"first","affiliation":[{"name":"Icahn School of Medicine Division of Pediatric Gastroenterology & Nutrition, Department of Pediatrics, Mount Sinai, , New York, NY"},{"name":"Susan & Leonard Feinstein IBD Center , Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smyth","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine Division of Pediatric Gastroenterology & Nutrition, Department of Pediatrics, Mount Sinai, , New York, NY"},{"name":"Susan & Leonard Feinstein IBD Center , Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Cices","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Department of Dermatology, , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Mercurio","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine Division of Pediatric Gastroenterology & Nutrition, Department of Pediatrics, Mount Sinai, , New York, NY"},{"name":"Susan & Leonard Feinstein IBD Center , Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Helmus","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine Division of Pediatric Gastroenterology & Nutrition, Department of Pediatrics, Mount Sinai, , New York, NY"},{"name":"Susan & Leonard Feinstein IBD Center , Mount Sinai, New York, NY"},{"name":"Icahn School of Medicine Division of Gastroenterology, Department of Medicine, Mount Sinai, , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C","family":"Ungaro","sequence":"additional","affiliation":[{"name":"Susan & Leonard Feinstein IBD Center , Mount Sinai, New York, NY"},{"name":"Icahn School of Medicine Division of Gastroenterology, Department of Medicine, Mount Sinai, , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine Division of Pediatric Gastroenterology & Nutrition, Department of Pediatrics, Mount Sinai, , New York, NY"},{"name":"Susan & Leonard Feinstein IBD Center , Mount Sinai, New York, NY"},{"name":"Icahn School of Medicine Division of Gastroenterology, Department of Medicine, Mount Sinai, , New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,24]]},"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag036\/68157441\/otag036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag036\/68157441\/otag036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:28:36Z","timestamp":1777098516000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article\/doi\/10.1093\/crocol\/otag036\/8662324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag036","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"otag036"}}